HBIO
Harvard Bioscience, Inc.
HBIO has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
HBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Weak |
HBIO's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HBIO PE Valuation
HBIO has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
HBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Weakening | |
| Limited | |
| High |
HBIO has the edge over NVO on the outlook, with more favorable earnings expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.59 | +$9.51 |
| Q2 2026 | -$2.31 | +$10.59 |
| Q1 2026 | -$2.17 | +$10.93 |
| Q4 2025 | -$12.80 | -$10.00 |
| Q3 2025 | -$12.10 | -$8.80 |
| Q2 2025 | -$12.90 | -$10.40 |
| Q1 2025 | -$13.10 | -$11.10 |
| Q4 2024 | -$2.80 | -$2.00 |
HBIO is still losing money, but far less than before: $2.59 per share over the past year, against $13.10 at its worst in early 2025.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over HBIO on earnings quality, reporting a profit while its opponent remains loss making.
HBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22.2M | +7.8% |
| Q2 2026 | $22.7M | +11% |
| Q1 2026 | $20.8M | -4.7% |
| Q4 2025 | $23.7M | -3.3% |
| Q3 2025 | $20.6M | -6.3% |
| Q2 2025 | $20.5M | -11% |
| Q1 2025 | $21.8M | -11% |
| Q4 2024 | $24.6M | -13% |
HBIO's revenue is recovering but still below its 2021 peak: $22M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.2% | -6.1 points |
| Q2 2026 | -4.3% | -0.3 points |
| Q1 2026 | -5.7% | +223 points |
| Q4 2025 | 7.2% | +7.2 points |
| Q3 2025 | 1% | +9.5 points |
| Q2 2025 | -4% | +5 points |
| Q1 2025 | -228% | -219 points |
| Q4 2024 | 0% | -1 points |
HBIO's operating margin was −5.2% last quarter, down 6.1 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over HBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over HBIO on profitability, with a higher operating margin.
HBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2M | -234% |
| Q2 2026 | -$363K | -114% |
| Q1 2026 | -$1.1M | -144% |
| Q4 2025 | -$545K | -138% |
| Q3 2025 | $877K | +$2.6M |
| Q2 2025 | $2.7M | +$4.3M |
| Q1 2025 | $2.5M | +226% |
| Q4 2024 | $1.4M | -59% |
HBIO's free cash flow has turned negative after years in the green: −$3M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over HBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
HBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +35K shares |
| 1 year | +2.4% | +105K shares |
| 3 years | +6.8% | +292K shares |
| 5 years | +15% | +582K shares |
| Available history | +21% | +780K shares |
HBIO has 5M diluted shares, up 2.4% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over HBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
HBIO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 10.3x | High |
| Q2 2026 | 6.2x | High |
| Q1 2026 | 5.5x | High |
| Q4 2024 | 43.1x | High |
| Q3 2024 | 30.5x | High |
| Q2 2024 | 15.6x | High |
| Q1 2024 | 6.5x | High |
| Q4 2023 | 3.7x | Elevated |
HBIO's net debt is about 10 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over HBIO on leverage, with a lower net debt burden relative to earnings.
HBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.8 | Neutral |
| Stochastic | 83.0 | Overbought |
HBIO's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
HBIO PE vs Healthcare Sector
HBIO has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.42 | 9.4% above |
| 20 week MA | $7.52 | 22% above |
| 50 week MA | $6.58 | 40% above |
| 100 week MA | $7.00 | 32% above |
| 200 week MA | $23.1 | 60% below |
HBIO has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
HBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.4 | $40.8 | +39% |
| 2021 | $40.8 | $71.0 | +74% |
| 2022 | $71.0 | $27.3 | -62% |
| 2023 | $27.3 | $53.5 | +96% |
| 2024 | $53.5 | $19.8 | -63% |
| 2025 | $19.8 | $7.02 | -65% |
| 2026 YTD | $7.02 | $9.21 | +31% |
HBIO has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.